Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Bansal, Shruti ^a   Harjai, Kusum ^a   Chhibber, Sanjay ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Aeromonas punctata; Capsule depolymerase; Gentamicin; Innate immune response; Klebsiella pneumoniae

Indexed keywords

CYTOKINE; GENTAMICIN; VIRULENCE FACTOR; IMMUNOLOGIC FACTOR; POLYSACCHARIDE LYASE;

AEROMONAS PUNCTATA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INNATE IMMUNITY; KIDNEY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LIVER; LUNG; LUNG INFECTION; MALE; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; SEPTICEMIA; SPLEEN; AEROMONAS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GERMFREE ANIMAL; HUMAN; IMMUNOLOGY; KLEBSIELLA INFECTION; MICROBIOLOGY; PHYSIOLOGY;

AEROMONAS; ANIMALS; CYTOKINES; FEMALE; GENTAMICINS; HUMANS; IMMUNOLOGIC FACTORS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; POLYSACCHARIDE-LYASES; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84906839851     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-456     Document Type: Article

References (45)

1. Stanier RY, Adelberg EA, Ingraham JL. Chapter 19. General microbiology 1977, 593-604. London: MacMillan, 4.
2. Lesinski GB, Westernick MA. Vaccines against polysaccharide antigens. Curr Drug Targets Infect Disord 2001, 1:325-334.
3. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine- induced immune response. Vaccine 2011, 29:4881-4890.
4. Guerry P, Poly F, Riddle M, Maue AC, Chen YH, Monteiro MA. Campylobacter polysaccharide capsules: virulence and vaccines. Front Cell Infect Microbiol 2012, 15:2-7.
5. Cress BF, Englaender JA, He W, Kasper D, Linhardt RJ, Koffas MAG. Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules. FEMS Microbiol Rev 2014, 1-38.
6. Kuberan B, Linhardt R. Carbohydrate based vaccines. Curr Org Chem 2000, 4:653-677.
7. Wilson RP, Raffatellu M, Chessa D, Winter SE, Tu¨kel C, Ba¨umler AJ. The Vi-capsule prevents Toll-like receptor 4 recognition of Salmonella. Cell Microbiol 2008, 10:876-890.
8. Thurlow LR, Thomas VC, Fleming SD, Hancock LE. Enterococcus faecalis capsular polysaccharide serotypes C and D and their contributions to host innate immune evasion. Infect Immun 2009, 77:5551-5557.
9. Merino S, Toma JM. Bacterial capsules and evasion of immune responses. Encyclopedia of life sciences (ELS) 2010, Chichester: John Wiley & Sons, Ltd.
10. Llobet E, Tomas JM, Bengoechea JA. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiol 2008, 154:3877-3886.
11. Wu M-C, Lin T-L, Hsieh P-F, Yang H-C, Wang J-T. Isolation of genes involved in biofilm formation of a Klebsiella pneumoniae strain causing pyogenic liver abscess. PLoS One 2011, 6:1-11.
12. Cano V, Moranta D, Llobet-Brossa E, Bengoechea JA, Garmendia J. Klebsiella pneumoniae triggers a cytotoxic effect on airway epithelial cells. BMC Microbiol 2009, 9:156.
13. Mizuta K, Ohta M, Mori M, Hasegawa T, Nakashima I, Kato N. Virulence for mice of Klebsiella strains belonging to the O1 group relationship to their capsular (K) types. Infect Immun 1983, 40:56-61.
14. Hsu CR, Lin TL, Pan YJ, Hsieh PF, Wang JT. Isolation of a bacteriophage specific for a New capsular type of Klebsiella pneumoniae and characterization of its polysaccharide depolymerase. PLoS One 2013, 8:70092.
15. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001, 358:135-138.
16. Stewart PS. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob Agents Chemother 1996, 40:2517-2522.
17. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R. Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr Prot Pept Sci 2012, 13:699-722.
18. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001, 48:5-16.
19. Bansal S, Soni SK, Harjai K, Chhibber S. Aeromonas punctata derived depolymerase that disrupts the integrity of Klebsiella pneumoniae capsule: optimization of depolymerase production. J Basic Microbiol 2013, 53:1-10.
20. Held TK, Mielke MEA, Chedid M, Unger M, Trautman M, Huhn D, Cross AS. Granulocyte colony-stimulating factor worsens the outcome of the experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria. Blood 1998, 91:2525-2533.
21. Yadav V, Sharma S, Harjai K, Mohan H, Chhibber S. Induction and resolution of lobar pneumonia following intranasal instillation with Klebsiella pneumoniae in mice. Indian J Med Res 2003, 118:47-52.
22. Hampton MB, Winterbourn CC. Methods for quantifying phagocytosis and bacterial killing by human neutrophils. J Immunol Met 1999, 232:15-22.
23. Carpenter JL. Klebsiella pulmonary infections: occurrence at one medical center and review. Rev Infect Dis 1990, 12:672-682.
24. Yadav V, Sharma S, Harjai K, Mohan H, Chhibber S. Lipopolysaccharide-mediated protection against Klebsiella pneumoniae induced lobar pneumonia: intranasal vs intramuscular route of immunization. Folia microbial 2005, 50:83-86.
25. Evrard B, Balestrino D, Dosgilbert A, Bouya-Gachancard JLJ, Charbonnel N, Forestier C, Tridon A. Roles of Capsule and Lipopolysaccharide O Antigen in Interactions of Human Monocyte-Derived Dendritic Cells and Klebsiella pneumoniae. Infect Immun 2010, 78:210-219.
26. Kumarasamy KK, Toleman MA, Wals TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
27. Wu G, Fan X, Li L, Wang H, Ding J, Hongbin W, Zhao R, Gou L, Shen Z, Xi T. Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli. Int J Antimicrob Agents 2010, 35:250-254.
28. Kabha K, Nissimov L, Athamna A, Keisari Y, Parolis H, Parolis LA, Grue RM, Schlepper-Schafer J, Ezekowitz AR, Ohman DE. Relationship among capsule structure. Infect Immun 1995, 63:847-852.
29. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005, 436:1171-1175.
30. Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the aminoglycosides?. Int J Antimicrob Agents 2009, 33:201-205.
31. Lavender HF, Jagnow JR, Clegg S. Biofilm formation in vitro and virulence in vivo of mutants of Klebsiella pneumoniae. Infect Immun 2004, 72:4888-4890.
32. Kristian SA, Birkenstock TA, Sauder U, Mack D, Go¨tz F, Landmann R. Biofilm formation induces C3a release and protects staphylococcus epidermidis from IgG and complement deposition and from neutrophil-dependent killing. J Infect Dis 2008, 197:1028-1035.
33. Brown DT. Carbocysteine. Drug Intell Clin Pharm 1988, 22:603-607.
34. Merino S, Camprubi S, Alberti S, Benedi VJ, Tomas JM. Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing. Infect Immun 1992, 60:2529-2535.
35. Mushtaq N, Redpath MB, Luzio JP, Taylor PW. Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob Agents Chemother 2004, 11:1503-1508.
36. Mushtaq N, Redpath MB, Luzio JP, Taylor PW. Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase. J Antimicrob Chemother 2005, 56:160-165.
37. Scorpio A, Chabot DJ, Day WA, O'Brien DK, Vietri NJ, Itoh Y, Mohamadzadeh M, Friedlander AM. Poly-y¨-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob Agents Chemother 2007, 51:215-222.
38. Scorpio A, Tobery SA, Ribot WJ, Friedlander AM. Treatment of experimental anthrax with recombinant capsule depolymerase. Antimicrob Agents Chemother 2008, 13:1014-1020.
39. Scorpio A, Chabot DJ, Day WA, Hoover TA, Friedlander AM. Capsule depolymerase overexpression reduces Bacillus anthracis virulence. Microbiol 2010, 156:1459-1467.
40. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Muraoka A, Sugai M, Hiramatsu K, Honke K, Matsuzaki S. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J Infect Dis 2007, 196:1237-1247.
41. Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 2005, 49:1225-1228.
42. Witzenrath M, Schmeck B, Doehn JM, Tschernig T, Zahlten J, Loeffler JM, Zemlin M, Mu¨ller H, Gutbier B, Schu¨tte H, Hippenstiel S, Fischetti VA, Suttorp N, Rosseau S. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit Care Med 2009, 37:642-649.
43. Zelmer A, Martin MJ, Gundogdu O, Birchenough G, Lever R, Wren BW, Luzio JP, Taylor PW. Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1. Microbiol 2010, 156:2205-2215.
44. Loessner MJ, Kramer K, Ebel F, Scherer S. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 2002, 44:335-349.
45. Baquero F, Hsueh PR, Paterson DL, Rossi F, Bochicchio GV, Gallagher G, Lantz K, Villasenor JB, McCarroll K, Abramson MA, Chow JW. In Vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from study for monitoring antimicrobial resistance trends (SMART). Surg Infect 2009, 10:99-104.